Immunotherapy

An interview with Jason Luke, an assistant professor of Medicine at the University of Chicago Medicine, reveals that he thinks immunotherapy should become a main treatment for many patients with melanoma.

The FDA's breakthrough designation is meant to expedite the development of therapies that offer substantial benefits over existing options.

In the oncology world, gastrointestinal cancers may be the next in line to realize the promise of immunotherapy.

It has been an "embarrassment of riches" in the treatment paradigm for patients with non–small cell lung cancer (NSCLC) with two approved two PD-1 agents.

The immunotherapy will continue to be offered in the phase 3 trial and compassionate use programs.

When it comes to gastrointestinal (GI) cancers, there’s quite a disparity in the gains that research is bringing us.

Medical illustrations by Erin Moore explaining novel treatments for glioblastoma.

Q & A with Naiyer Rizvi on the progression of immunotherapy for non-small cell lung cancer (NSCLC).

The breakthrough designation will expedite the development and review of this novel T-cell therapy in synovial sarcoma.

"This is what I've devoted my career to, and it is gratifying to see that really come to pass," says Robert Ferris.

The combination of Opdivo and radiation therapy may provide better disease control and a boost in overall survival in patients with melanoma whose disease has metastasized to the brain.

"No recent cancer advance has been more transformative than immunotherapy," said ASCO president Julie M. Vose.

To better understand the implications of the expanded approval and the potential for Opdivo, we spoke to Jedd D. Wolchok from Memorial Sloan Kettering Cancer Center.

The study was stopped early after an independent monitoring panel determined the primary endpoint of improvement in OS was met.

The approval was based on data from the phase 3 CheckMate-067 trial.

For some patients, doctors recommend treatment after surgery to reduce the risk of melanoma developing again.

Amid all the excitement over recently approved immunotherapies and targeted drugs for the treatment of later-stage melanoma is an important emerging message: In many cases, two is better than one.

Melanoma has been a primary focus in immunotherapy research because of intriguing evidence that some people's immune systems are better able to keep the cancer in check.

To gain insight into the research needed in glioblastoma, we interviewed Robert M. Prins, an associate professor in residence at UCLA.

Recent FDA approvals have added to the growing number of treatment options for patients with advanced melanoma.

Targeted drugs, as well as immunotherapies, are beginning to change the treatment outlook for people with advanced non-small cell lung cancer.

Gene therapy has the potential to deliver long-lasting remissions for patients with advanced B-cell malignancies who already have undergone an allogeneic hematopoietic stem cell transplant.

After a median follow-up of 10 months, the overall response rate in patients with PD-L1-expressing metastatic breast cancer was 33.3 percent.

The addition of the PD-1 inhibitor Keytruda (pembrolizumab) to an established multiple myeloma regimen elicited responses in 76 percent of 17 patients with relapsed/refractory disease.

Genetically engineered T cells eradicated multiple myeloma cells in a single patient with advanced disease.

Immunotherapies continue to be studied and approved across multiple tumor types, among them, malignancies of the central nervous system.

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor (CAR) T-cell therapy.

The dramatic and often practice-changing findings demonstrated by trials of immunotherapies in melanoma and lung cancer may soon be reflected in the treatment of bladder cancer.

To gain insight into the recent flurry of FDA approvals in melanoma, CURE spoke with Tim Turnham, the executive director of the Melanoma Research Foundation.

"It's not because there's evidence that they don't work — it's just that there's no evidence at all," Maurie Markman says.